DRMA Stock Price, Dermata Therapeutics, Quote, Chart

Market Summary

USD4.20-1.00

Delayed

-19.23%

DRMA Stock Price

View Fullscreen

DRMA RSI Chart

DRMA Valuation

Market Cap

28.0M

Price/Earnings (Trailing)

-3.22

Price/Sales (Trailing)

113.16

Price/Free Cashflow

-3.75

DRMA Price/Sales (Trailing)

DRMA Profitability

Return on Equity

-228.17%

Return on Assets

-167.75%

Free Cashflow Yield

-26.68%

DRMA Fundamentals

DRMA Revenue

Revenue (TTM)

247.2K

DRMA Earnings

Earnings (TTM)

-8.7M

Earnings Growth (Yr)

-39.91%

Earnings Growth (Qtr)

-46.87%

Breaking Down DRMA Revenue

Last 7 days

1075%

Last 30 days

1358.6%

Last 90 days

819.6%

Trailing 12 Months

72.0%

How does DRMA drawdown profile look like?

DRMA Financial Health

Current Ratio

7.66

DRMA Investor Care

Shares Dilution (1Y)

321.61%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q4
2024	0	0
2023	155.4K	247.2K
2022	0	63.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dermata Therapeutics, Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 06, 2022	bradrick brittany	acquired	-	-	9,810	-
Oct 06, 2022	scott kathleen d.	acquired	-	-	11,359	-
Oct 06, 2022	sandler andrew seth	acquired	-	-	10,120	-
Oct 06, 2022	fisher mary	acquired	-	-	9,810	-
Oct 06, 2022	wierenga wendell	acquired	-	-	20,654	-
Oct 06, 2022	hale david f	acquired	-	-	30,155	-
Jul 07, 2022	sandler andrew seth	acquired	-	-	8,874	-
Jul 07, 2022	hale david f	acquired	-	-	26,441	-
Jul 07, 2022	wierenga wendell	acquired	-	-	18,110	-
Jul 07, 2022	fisher mary	acquired	-	-	8,602	-

Which funds bought or sold DRMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	1.00	1.00	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-132,980	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-93.75	51.00	193	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-2,390	4,930	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-10.62	-1,558	2,358	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	8,203	8,203	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	6.00	6.00	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	7,031	7,031	-%
May 13, 2024	UBS Group AG	reduced	-55.71	-8.00	15.00	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-2,545	4,919	-%

Are Funds Buying or Selling DRMA?

Are funds buying DRMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DRMA

No. of Funds

Unveiling Dermata Therapeutics, Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	412,111	SC 13G
Jun 01, 2023	intracoastal capital, llc	4.99%	143,944	SC 13G
Mar 31, 2023	hale david f	1.9%	44,833	SC 13D/A
Mar 30, 2023	proehl gerald t	9.6%	233,030	SC 13D/A
Jan 18, 2023	proehl gerald t	28.9%	3,721,035	SC 13D/A
May 05, 2022	proehl gerald t	37.7%	3,658,445	SC 13D/A

Recent SEC filings of Dermata Therapeutics, Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 15, 2024	8-K	Current Report
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
Mar 26, 2024	DEFA14A	DEFA14A
Mar 26, 2024	DEF 14A	DEF 14A
Mar 26, 2024	ARS	ARS
Mar 21, 2024	8-K	Current Report

Peers (Alternatives to Dermata Therapeutics, Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Dermata Therapeutics, Inc News

Latest updates

Dermata Therapeutics, Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4
Revenue	29.7%	69.00	53.00	38.00	-
Operating Expenses	44.3%	3,204	2,220	2,278	1,712
S&GA Expenses	-100.0%	-	1,085	1,085	822
R&D Expenses	41.0%	1,601	1,135	1,193	889
Interest Expenses	-	-	-	38.00	42.00
Income Taxes	-	-	-	-	150*
Net Income	-46.9%	-3,134	-2,133	-2,240	-1,669
Net Income Margin	-11.5%	-35.15*	-31.53*	-58.33*	-151.18*
Free Cashflow	-135.7%	-2,704	-1,147	-1,649	-1,825

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-35.1%	5,180	7,979	7,323	8,713	9,295	6,944	8,975	11,026	9,044	11,624	13,686	1,137	871	605	2,066
Current Assets	-	-	-	-	-	-	-	-	-	-	11,624	13,686	1,137	-	605	2,065
Cash Equivalents	-36.4%	4,734	7,438	6,631	8,439	8,767	6,241	8,067	10,628	8,191	10,799	12,603	427	1,330	530	1,992
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	322*
Liabilities	-15.5%	1,372	1,624	917	683	1,207	923	1,504	1,366	1,191	1,517	1,195	1,643	2,713	3,783	2,276
Current Liabilities	-	-	-	-	-	-	-	-	-	-	1,517	1,195	1,643	-	3,783	1,723
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	556	731
Shareholder's Equity	-40.1%	3,808	6,355	6,407	8,030	8,088	6,022	7,471	9,660	7,853	10,107	12,491	-	712	-	-
Retained Earnings	-5.9%	-56,522	-53,387	-51,253	-49,534	-47,833	-45,593	-43,923	-41,499	-38,768	-35,982	-33,429	-31,716	-	-28,079	-24,843
Additional Paid-In Capital	1.0%	60,329	59,743	57,660	57,564	55,921	51,615	51,393	51,158	46,620	46,089	45,919	31,203	-	-	-
Shares Outstanding	69.5%	6,661	3,931	3,189	3,189	2,388	770	756	631	521	521	521	119	-	119	-
Float	-	-	-	-	4,800	-	-	-	4,000	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-135.7%	-2,704	-1,147	-1,771	-1,840	-1,649	-1,825	-2,561	-1,839	-2,607	-1,803	-2,210	-903	-776	-535	-1,369	-	-
Share Based Compensation	357.1%	587	128	131	131	131	221	235	262	213	489	143	994	280	-	-	-	-
Cashflow From Financing	-100.0%	-	1,954	-35.42	1,512	4,175	-	200*	4,276	-	-626*	14,386	-	1,576	313	1,386	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DRMA Income Statement

2024-03-31

Statements of Operations (unaudited) - USD ($)	3 Months Ended
Statements of Operations (unaudited) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 1,600,741	$ 1,192,633
General and administrative	1,602,819	1,085,049
Total operating expenses	3,203,560	2,277,682
Loss from operations	(3,203,560)	(2,277,682)
Other income and expenses:
Interest income, net	69,298	37,540
Net loss	$ (3,134,262)	$ (2,240,142)
Net loss per share of common stock, basic and diluted	$ (0.47)	$ (2.27)
Weighted-average basic and diluted shares	6,660,840	985,848

DRMA Balance Sheet

2024-03-31

Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets:
Cash and cash equivalents	$ 4,733,681	$ 7,438,135
Prepaid expenses and other current assets	446,075	540,499
Total assets	5,179,756	7,978,634
Liabilities:
Accounts payable	822,546	866,028
Accrued and other current liabilities	549,220	757,588
Total liabilities	1,371,766	1,623,616
Stockholders' Equity:
Common Stock, par value $0.0001, 250,000,000 shares authorized; 6,660,840 shares issued and outstanding as of March 31, 2024; 3,930,840 shares issued and outstanding as of December 31, 2023, respectively.	666	393
Additional paid-in capital	60,329,464	59,742,503
Accumulated deficit	(56,522,140)	(53,387,878)
Total stockholders' equity	3,807,990	6,355,018
Total liabilities and stockholders' equity	$ 5,179,756	$ 7,978,634

About Dermata Therapeutics, Inc

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

CEO	Mr. Gerald T. Proehl
WEBSITE	dermatarx.com
INDUSTRY	Biotechnology
EMPLOYEES	8

Dermata Therapeutics, Inc Frequently Asked Questions

What is the ticker symbol for Dermata Therapeutics, Inc? What does DRMA stand for in stocks?

DRMA is the stock ticker symbol of Dermata Therapeutics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dermata Therapeutics, Inc (DRMA)?

As of Fri May 17 2024, market cap of Dermata Therapeutics, Inc is 28.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DRMA stock?

You can check DRMA's fair value in chart for subscribers.

What is the fair value of DRMA stock?

You can check DRMA's fair value in chart for subscribers. The fair value of Dermata Therapeutics, Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dermata Therapeutics, Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DRMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dermata Therapeutics, Inc a good stock to buy?

The fair value guage provides a quick view whether DRMA is over valued or under valued. Whether Dermata Therapeutics, Inc is cheap or expensive depends on the assumptions which impact Dermata Therapeutics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRMA.

What is Dermata Therapeutics, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DRMA's PE ratio (Price to Earnings) is -3.24 and Price to Sales (PS) ratio is 113.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRMA PE ratio will change depending on the future growth rate expectations of investors.